Orakl Oncology

Cancer complexity leads to a 96% failure rate of drug candidates in clinical trials and a shortage of new treatments. Orakl Oncology’s ambition is to finally address the heterogeneity of cancer and patient specificities as early as possible in drug development. By creating a collection of avatars of patients’ tumors, they predict how each patient will respond to future drugs. Orakl Oncology is an interdisciplinary techbio platform that combines best-in-class biology with deep clinical data and machine learning to efficiently discover and optimize new treatments for the right patients. Thanks to their technology, Orakl Oncology works with drug developers to bring better drugs to patients, faster.